Okay, here’s a verification and correction of the provided text, based on information available as of today, November 2, 2023.I will highlight the changes and provide explanations. Since the text is dated January 22, 2026, I will focus on identifying inaccuracies relative to the present and what would likely be different by that future date, based on current trends.
Original Text (with corrections/comments embedded):
“`html
According to the national Eye institute, glaucoma constitutes the foremost cause of blindness and vision loss in the United States. Notably, it has no symptoms early on, and can only be diagnosed through a comprehensive dilated eye exam. although some treatments for the condition are available, it has no cure, and significant unmet need remains for the patient population.
One area of interest for new glaucoma treatments is cell and gene therapy. This year for glaucoma Awareness Month, which is observed annually in January by the patient and clinician communities, CGTLive® reached out to Jeffrey Goldberg, MD, PhD, a professor and chair of ophthalmology at the Byers Eye Institute at Stanford University, to learn more about how cell and gene therapy might help to address unmet needs in glaucoma.
CGTLive: Can you give some background on unmet needs in glaucoma?
Jeffrey Goldberg, MD, PhD: The biggest unmet need is for neuroprotective therapies-to prevent patients from losing their vision-and therapies that can restore vision in those patients who have already lost vision.
how could glaucoma potentially be addressed by cell or gene therapy approaches?
In early or moderate disease, gene therapy could deliver a neuroprotective or even neuroenhancing therapy that prevents vision loss, or gives a booster shot to sick but not yet dead retinal ganglion cells, thereby protecting or restoring vision. Cell therapy could be used to replace
Worth a look